{"id":"W4200407033","doi":"10.1038/s41591-021-01539-8","title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Stanford Cancer Institute; National Center for Advancing Translational Sciences; Genentech; National Institutes of Health; Astellas Pharma; Swedish Orphan Biovitrum; Novo Nordisk; National Heart, Lung, and Blood Institute; Scheme for Promotion of Academic and Research Collaboration; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Sierra Oncology; F. Hoffmann-La Roche; CTI Biopharma; Pfizer; Incyte; Celgene; National Cancer Institute; Gilead Sciences; Chugai Pharmaceutical; ARUP Laboratories; José Carreras Leukämie-Stiftung; Amgen; Cilag; University of Texas MD Anderson Cancer Center; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Systemic mastocytosis; Medicine; Clinical endpoint; Internal medicine; Interim analysis; Adverse effect; Neutropenia; Gastroenterology; Tryptase; Anemia; Phases of clinical research; Clinical trial; Oncology; Bone marrow; Mast cell; Immunology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00653228,0.001117412,0.002074025,0.0002547974,0.0003164037,0.0010495,0.0004884918,0.0008887889,0.003522595],"category_scores_gemma":[0.002860549,0.0002776961,0.001933483,0.0002408116,0.0004045195,0.001015199,0.0004380036,0.002190117,0.0007367673],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004199102,"about_ca_system_score_gemma":0.0008015365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001434366,"about_ca_topic_score_gemma":0.0004013123,"domain_scores_codex":[0.9985535,0.00086308,0.00006408249,0.0001660144,0.0001613097,0.0001920484],"domain_scores_gemma":[0.9986143,0.0004617677,0.0004011945,0.0001787387,0.0001146459,0.0002293471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8844377,0.005965145,0.01261328,0.0009942856,0.004009775,0.0003052586,0.0001341891,0.005173078,0.01204444,0.0004934827,0.01078625,0.06304307],"study_design_scores_gemma":[0.5661914,0.3389546,0.06312729,0.0001369818,0.004493799,0.0009351089,0.00008641501,0.00727823,0.006620856,0.001788882,0.01029447,0.00009189921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9779222,0.004512386,0.002406688,0.0009216199,0.0002983699,0.002336775,0.00624263,0.0003203588,0.0050389],"genre_scores_gemma":[0.9822773,0.000837805,0.002593254,0.0007108822,0.0001951287,0.003165811,0.007546428,0.00006311684,0.002610307],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00653228,"threshold_uncertainty_score":0.03454643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009858173662321577,"score_gpt":0.2884010356378187,"score_spread":0.2785428619754971,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}